Period:
Draw Mode:
| Volume | 151,472 |
|
|||||
| News | - | ||||||
| Day High | 1.528 | Low High |
|||||
| Day Low | 1.42 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Revelation Biosciences Inc | REVB | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.09 | -5.88% | 1.44 | 18:02:17 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.46 | 1.42 | 1.528 | 1.45 | 1.53 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 991 | 151,472 | $ 1.47 | $ 222,689 | - | 1.27 - 99.40 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 17:51:24 | 1 | $ 1.48 | USD |
Revelation Biosciences Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 5.14M | 3.57M | 3.47M | $ - | $ - | -32.41 | -0.10 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | 1.96M | 34.20% |
Revelation Biosciences News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical REVB Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.41 | 1.55 | 1.27 | 1.40 | 195,143 | 0.03 | 2.13% |
| 1 Month | 2.10 | 2.50 | 1.27 | 1.84 | 413,474 | -0.66 | -31.43% |
| 3 Months | 6.524 | 11.3925 | 1.27 | 5.96 | 545,591 | -5.08 | -77.93% |
| 6 Months | 9.3135 | 17.549 | 1.27 | 10.98 | 1,142,099 | -7.87 | -84.54% |
| 1 Year | 93.45 | 99.40 | 1.27 | 27.62 | 2,005,460 | -92.01 | -98.46% |
| 3 Years | 293.30 | 341.25 | 1.27 | 36.78 | 2,145,140 | -291.86 | -99.51% |
| 5 Years | 293.30 | 341.25 | 1.27 | 36.78 | 2,145,140 | -291.86 | -99.51% |
Revelation Biosciences Description
| Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. It has several product candidates in development. REVTx-99, the lead therapeutic candidate, is an intranasal immunomodulator to prevent or treat infections caused by various respiratory viruses such as SARS-CoV-2, including its variants, influenza A and B, parainfluenza, rhinovirus, and RSV. REVTx-99 is also being developed for other indications such as: allergic rhinitis and chronic nasal congestion. REVTx-200 is an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. REVTx-200 is based on the same technology used in REVTx-99. |